# Kristina Burow

> Kristina Burow is a Series A investor at ARCH Venture Partners backing Biotechnology. See 23 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners)
- Location: San Francisco, United States
- Total investments: 23
- Last investment: Jan 2026
- Lead investor: 57%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/kristina-burow-4a8836b

Kristina Burow is a Series A investor at ARCH Venture Partners in San Francisco focused on Biotechnology and Therapeutics. Kristina Burow is based out of San Francisco, California, and is the Managing Director of ARCH Venture Partners. Kristina previously worked at Novartis Venture Fund as a Associate. Kristina Burow attended the University of Chicago Booth School of Business.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 14 | 61% |
| Therapeutics | 10 | 43% |
| Health Care | 9 | 39% |
| Medical | 7 | 30% |
| Pharmaceutical | 4 | 17% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 11 | 48% |
| Series B | 8 | 35% |
| Series C | 2 | 9% |
| Seed | 1 | 4% |
| Venture - Series Unknown | 1 | 4% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Mirador Therapeutics | Mirador Therapeutics develops precision medicines for immune-mediated inflammatory and fibrotic diseases using an integrated discovery and development platform. The company’s Mirador360 engine combines human genetics, multi-modal data, and analytical tools to identify therapeutic targets, support patient stratification, and inform drug design. Itsofferings include research programs and pipeline assets aimed at conditions such as chronic inflammation and tissue fibrosis. Mirador Therapeutics works with scientific and medical stakeholders to advance targeted therapeutic candidates through preclinical and clinical development. | $250M | Series B | Jan 12, 2026 |  |
| Tenvie Therapeutics | Tenvie Therapeutics is a biotechnology company founded to improve patients' lives with neurological, cardiometabolic, and ophthalmic diseases. The company is focused on developing small molecules targeting brain inflammation, metabolic dysfunction, and lysosomal issues, with a robust pipeline inherited from Denali Therapeutics. Tenvie isprogressing a range of therapeutics aimed at addressing neurological, cardiometabolic, and ophthalmic conditions. Its collection of fully owned, highly brain-penetrant, and precisely designed peripherally restricted small molecules targets three main factors of disease: alleviating inflammation, correcting metabolic dysfunction, and rejuvenating lysosomal function. | $200M | Series A | Jan 08, 2025 |  |
| Metsera | Metsera operates as a clinical-stage biopharmaceutical company. | $215M | Series B | Nov 13, 2024 |  |
| Autobahn Therapeutics | Autobahn Therapeutics is focused on improving life health for people affected by CNS disorders. Autobahn is leveraging a deep understanding of validated human biology coupled with its brain-targeting chemistry platform to develop thyroid hormone receptor beta agonist therapies that harness the regenerative power of the human body. The company’spipeline is led by ABX-002 for the treatment of multiple sclerosis and adrenomyeloneuropathy (AMN), a rare genetic disorder. Autobahn Therapeutics is based in San Diego. | $100M | Series C | Jul 24, 2024 |  |
| Metsera | Metsera operates as a clinical-stage biopharmaceutical company. | $290M | Series A | Apr 18, 2024 |  |
| Mirador Therapeutics | Mirador Therapeutics develops precision medicines for immune-mediated inflammatory and fibrotic diseases using an integrated discovery and development platform. The company’s Mirador360 engine combines human genetics, multi-modal data, and analytical tools to identify therapeutic targets, support patient stratification, and inform drug design. Itsofferings include research programs and pipeline assets aimed at conditions such as chronic inflammation and tissue fibrosis. Mirador Therapeutics works with scientific and medical stakeholders to advance targeted therapeutic candidates through preclinical and clinical development. | $400M | Series A | Mar 21, 2024 |  |
| Remix Therapeutics | Remix Therapeutics is a biotechnology company that develops novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways. | $60M | Venture - Series Unknown | Jan 03, 2024 |  |
| Magnet Biomedicine | Magnet Biomedicine is a biotechnology research platform specializing in discovering true molecular glues.Magnet Biomedicine leverages its TrueGlue discovery platform, which utilizes the latest advancements in human biology and proteomics. This platform identifies specialized adhesives optimized to maximize therapeutic effectiveness whiledelivering significant advantages, such as enhancing selectivity, fostering biological synergy on specific targets, and addressing previously challenging-to-target proteins. Magnet Biomedicine is actively harnessing the vast untapped potential of TrueGlues to address various disease areas and biological mechanisms, including but not limited to cancer, cardiovascular disease, and immune disorders. | $50M | Series A | Sep 19, 2023 |  |
| Orbital Therapeutics | Orbital Therapeutics aims to enhance global health by unleashing the full potential of RNA-based medicines to treat human disease in ways that were not previously possible. To produce an extended portfolio of medications, the company is developing an innovative platform at the confluence of RNA technology, delivery techniques, data analytics, andautomation. | $270M | Series A | Apr 26, 2023 |  |
| Pretzel Therapeutics | Pretzel was founded by some of the world’s foremost academics in mitochondrial biology, and we benefit from the leadership of accomplished experts in drug discovery, drug development, and company formation. Our name is inspired by the focal point of our science, the mitochondrion, whose highly folded inner membrane is one of many fascinatingfeatures that make it unlike any other organelle in the body. | $72.5M | Series A | Sep 12, 2022 |  |

10 of 23 investments shown.

## Co-investors
- [Google Ventures](https://shizune.co/investors/profile/google-ventures) — VC Fund, 7 deals together
- [Newpath Management](https://shizune.co/investors/profile/newpath-management-l-p) — VC Fund, 7 deals together
- [Invus](https://shizune.co/investors/profile/invus) — VC Fund, 6 deals together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 5 deals together
- [Mubadala Capital Ventures](https://shizune.co/investors/profile/mubadala-ventures) — VC Fund, 4 deals together
- [Samsara BioCapital](https://shizune.co/investors/profile/samsara-biocapital) — VC Fund, 4 deals together

## About ARCH Venture Partners

VC Fund · Chicago, United States

ARCH invests primarily in companies co-founded by scientists and entrepreneurs, concentrating on bringing to market innovations in life sciences. They enjoy special recognition as a leader in the successful commercialization of technologies developed at academic research institutions and national laboratories.ARCH has raised ten venture fundstotaling over $3 billion and has invested in the venture capital rounds for more than 150 companies. ARCH investors include corporations, pension funds, endowment funds, financial institutions, and private investors.

5 contacts available at ARCH Venture Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Cindy Bayley | Affiliate | https://shizune.co/investors/profile/cindy-bayley |
| Clinton Bybee | Co-Founder and Managing Director | https://shizune.co/investors/profile/clinton-w-bybee |
| Hong Hou | Venture Partner | https://shizune.co/investors/profile/hong-hou |
| Keith Crandell | Co-founder & Managing Director | https://shizune.co/investors/profile/keith-l-crandell |
| Kristina Burow | Managing Director | https://shizune.co/investors/profile/kristina-burrow |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Kristina Burow invest in?

Kristina Burow invests primarily in Biotechnology, Therapeutics and Health Care startups, most often at Series A and Series B stage. Most of the 23 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Kristina Burow last invest?

The most recent investment recorded for Kristina Burow closed in Jan 2026. Shizune tracks 23 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co